# Alzheimer’s and Medical Cannabis: Utah Department of Health Guidelines > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/alzheimers-disease-cannabis-guidelines-utah-health/ > **Published:** 2026-04-01T15:05:30-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T10:32:48-04:00 > **Clinical Summary:** Explore Utah's Alzheimer's disease cannabis guidelines offering evidence-based clinical frameworks for medical cannabis use in neurodegenerative care. --- ✦ New CED Clinical Relevance  #76Notable Clinical Interest  Emerging findings or policy developments worth monitoring closely. ⚒ Cannabis News  |  CED Clinic Alzheimer’SNeurodegeneration[State Policy](https://cedclinic.com/will-the-coronavirus-force-states-to-legalize-marijuana/)Clinical GuidelinesBehavioral Symptoms Why This Matters Utah’s evidence-based guidelines represent one of the first state-level clinical frameworks for cannabis in Alzheimer’s care, providing structure for clinicians navigating this complex intersection. This signals growing institutional acceptance of cannabis as a legitimate therapeutic consideration in neurodegenerative disease management. Clinical Summary Utah’s Department of Health has published evidence-based guidelines for [medical cannabis](https://cedclinic.com/therapeutic-benefits-of-thc/) use in Alzheimer’s disease, reviewing available research on cannabinoids for neuroinflammation, behavioral symptoms, and neuroprotection. The guidelines likely address both THC and CBD applications for agitation, sleep disturbances, and appetite issues common in Alzheimer’s patients. While preclinical studies suggest anti-inflammatory and neuroprotective mechanisms, human clinical data remains limited, making these guidelines particularly valuable for standardizing care approaches. Dr. Caplan’s Take “Having state health departments create evidence-based cannabis guidelines for Alzheimer’s is exactly what we need — it forces honest evaluation of what we actually know versus what we hope. These frameworks help clinicians move beyond anecdotal approaches to systematic care.” Clinical Perspective 🧠 Clinicians should review Utah’s specific recommendations for dosing, strain selection, and monitoring parameters in Alzheimer’s patients. The guidelines likely emphasize starting with low-dose CBD for behavioral symptoms before considering THC, given the vulnerability of this population to cognitive side effects. This framework can inform practice even outside Utah until more comprehensive research emerges. 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/) Have thoughts on this? Share it: [𝕏 Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20Alzheimer%27s%20%7C%20Center%20for%20Medical%20Cannabis%20%7C%20Utah%20Department%20of%20Health%20and%20Human%20...%20%40drcaplan&url=https%3A//medicalcannabis.utah.gov/evidence-based-guidelines/alzheimers/)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A//medicalcannabis.utah.gov/evidence-based-guidelines/alzheimers/)[🦥 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20Alzheimer%27s%20%7C%20Center%20for%20Medical%20Cannabis%20%7C%20Utah%20Department%20of%20Health%20and%20Human%20...%20--%20via%20%40drcaplan.bsky.social%20https%3A//medicalcannabis.utah.gov/evidence-based-guidelines/alzheimers/)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan/)[📝 Read more on Substack](https://substack.com/@doctorapproved)[🔔 Subscribe via RSS](https://cedclinic.com/category/cannabis-news/feed/) 📰 Source: [https://medicalcannabis.utah.gov/evidence-based-guidelines/alzheimers/](https://medicalcannabis.utah.gov/evidence-based-guidelines/alzheimers/) Table of Contents - [FAQ](#FAQ)[What is the clinical relevance rating of this cannabis news?](#What_is_the_clinical_relevance_rating_of_this_cannabis_news) - [What medical conditions does this cannabis news relate to?](#What_medical_conditions_does_this_cannabis_news_relate_to) - [What type of cannabis development is being reported?](#What_type_of_cannabis_development_is_being_reported) - [Who should pay attention to this cannabis news?](#Who_should_pay_attention_to_this_cannabis_news) - [Why is this classified as “emerging” information?](#Why_is_this_classified_as_8220emerging8221_information) - [Related](#Related) ## FAQ #### What is the clinical relevance rating of this cannabis news? This article has been assigned CED Clinical Relevance #76 with a “Notable Clinical Interest” designation. This indicates emerging findings or policy developments that are worth monitoring closely by healthcare professionals. #### What medical conditions does this cannabis news relate to? The article focuses on Alzheimer’s disease and neurodegeneration. These are key areas where [cannabis research](https://cedclinic.com/pediatric-cannabis-certification-care-children/) and policy developments may have significant clinical implications. #### What type of cannabis development is being reported? This appears to be cannabis news related to [state policy](https://cedclinic.com/will-the-coronavirus-force-states-to-legalize-marijuana/) and clinical guidelines. The coverage suggests new policy developments or guideline changes that could impact clinical practice. #### Who should pay attention to this cannabis news? Healthcare providers, particularly those working with neurodegenerative conditions like Alzheimer’s disease, should monitor this development. Clinicians involved in [cannabis medicine](https://cedclinic.com/essential-oils-industrial-hemp-antimicrobial-benefits/) or considering cannabis treatments for patients may find this information relevant. #### Why is this classified as “emerging” information? The article is marked as “New” and deals with evolving state policy and clinical guidelines for cannabis use. These areas are rapidly changing, making it important for clinicians to stay updated on the latest developments. {“@context”: “https://schema.org”, “@type”: “NewsArticle”, “headline”: “Alzheimer’s | Center for [Medical Cannabis](https://cedclinic.com/therapeutic-benefits-of-thc/) | Utah Department of Health and Human Services”, “url”: “https://medicalcannabis.utah.gov/evidence-based-guidelines/alzheimers/”, “datePublished”: “2026-04-01T15:20:54Z”, “about”: “alzheimer s center medical cannabis utah”} [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence [Evidence based guidelines | Center for Medical Cannabis | Utah Department of Health and …](https://cedclinic.com/2026-cannabis-clinical-guidelines-utah-medical-cannabis/) Review Utah's comprehensive evidence-based guidelines for medical cannabis use across various conditions, including neurodegenerative diseases. [Read Guidelines](https://cedclinic.com/2026-cannabis-clinical-guidelines-utah-medical-cannabis/) CBD Gummies and Alzheimer's: What the Evidence Shows for Cognitive and Behavioral Support Explore current evidence on the use of CBD gummies for cognitive and behavioral support in Alzheimer's patients. Explore Evidence [Cannabis edibles in dementia care: What families should know – AZ Family](https://cedclinic.com/cannabis-use-in-dementia-care-families-know/) Learn important considerations for families regarding [cannabis edibles](https://cedclinic.com/decarboxylating-cannabis-process-why-how/) in dementia care settings. [Learn More](https://cedclinic.com/cannabis-use-in-dementia-care-families-know/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).